Management of regorafenib-related toxicities: a review

Therapeutic Advances in Gastroenterology
Saravanan K KrishnamoorthyMuhammad Wasif Saif

Abstract

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib's toxicities.

References

Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K MaedaY Arimoto
Sep 23, 1997·Scandinavian Journal of Gastroenterology·S J Lewis, K W Heaton
Apr 27, 2004·Cancer·Stephen T SonisUNKNOWN International Society for Oral Oncology
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Feb 16, 2005·Nature Biotechnology·Miles A FabianDavid J Lockhart
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Aug 1, 2007·The Oncologist·Jennifer K CarrollGary R Morrow
Sep 16, 2010·Nature Reviews. Cardiology·Michael S Ewer, Steven M Ewer
Mar 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus MrossOlaf Christensen
May 10, 2012·British Journal of Cancer·D StrumbergK Mross
Sep 14, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A E Bennion, A Molassiotis
Nov 28, 2012·Lancet·Tom Waddell, David Cunningham
Jan 26, 2013·Journal of Clinical Epidemiology·Morten Aa PetersenUNKNOWN EORTC Quality of Life Group
Mar 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SchultheisK B Mross
Apr 27, 2013·Molecular Cancer Therapeutics·Lotfi Abou-ElkacemWiltrud Lederle
Sep 3, 2013·Current Treatment Options in Oncology·Viswanath Reddy BelumMario E Lacouture
Oct 22, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Josep TaberneroCarmen J Allegra
Oct 24, 2013·European Journal of Clinical Pharmacology·Zexing WangXiaoxiang Guan
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn J RuddyCharles L Loprinzi
Sep 17, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J SastreC Pericay

❮ Previous
Next ❯

Citations

Sep 2, 2016·Biochimica Et Biophysica Acta·Ivan HaralampievPeter Müller
Oct 3, 2017·Case Reports in Oncology·Dominique BéchadeMarianne Fonck
Aug 25, 2019·Cancers·Yoshitaro ShindoHiroaki Nagano
Jul 9, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Diva SilvaIsabel F Almeida
Mar 13, 2020·International Journal of Cancer. Journal International Du Cancer·Sarun JuengpanichXiujun Cai
May 20, 2016·Journal of Lower Genital Tract Disease·Emma-Lee BourneJames Scurry
Mar 6, 2017·Oncology Reports·Nao KakizawaToshiki Rikiyama
Oct 12, 2018·Hepatic Oncology·Francesco TovoliAlessandro Granito
Apr 13, 2019·Journal of Experimental & Clinical Cancer Research : CR·N A SeebacherA M Merlot
Oct 27, 2020·International Journal of Clinical Oncology·Yasushi MurachiTaroh Satoh
Mar 3, 2021·Drugs & Aging·Monika Dudzisz-ŚledźPiotr Rutkowski
Jan 5, 2021·JHEP Reports : Innovation in Hepatology·Masatoshi KudoAndrew X Zhu
Apr 6, 2021·Current Hepatology Reports·Adeniji Nia, Renumathy Dhanasekaran
Jul 1, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Erwin WoffPatrick Flamen
Jun 13, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·N A Bhaskaran, L Kumar
Jul 31, 2021·World Journal of Gastroenterology : WJG·Hsuan YehTzung-Hai Yen
Sep 9, 2021·ACS Applied Materials & Interfaces·Seounghun KangHongje Jang
Oct 9, 2021·Journal of Cutaneous Pathology·Riyad N H SeervaiJonathan L Curry

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
biopsy
urine collection

Clinical Trials Mentioned

NCT01538680

Software Mentioned

CONSIGN

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Bulletin du cancer
Thierry André, Sarah N Dumont
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
Thomas J Ettrich, Thomas Seufferlein
© 2021 Meta ULC. All rights reserved